Patent ES-343874-A1 (ES)
Title: 6-substituted derivatives of 16-methyl-4-pregnene-3beta-ol-one
IPC: C07J5/00
Filed: 1967-08-05
Abstract: Novel steroids of the formula (wherein R1 is F, Cl, Br, CH 3 or CF 3 R2 and R3 are each H or together are -CH 2 - and the #6 double bond is optional) are prepared by (1) liberation of the 20-keto group in corresponding steroids containing a functionally modified 20-keto group (2) selective reduction of corresponding 3-ones with lithium aluminium tri-tert.-butoxy hydride or diborane in an inert solvent or with sodium borohydride in pyridine, methanol or anhydrous isopropanol or (3) treatment of corresponding 3#,17[alpha],20- trihydroxy steroid 3,20-dialkanoates with zinc and hydrolysis of the product with a strong base or a strong acid. 6[alpha],16[alpha] - Dimethyl - 4 - pregnen - 3# - ol - 20- one 20-semicarbazone is prepared reacting 6[alpha], 16[alpha]-dimethylprogesterone with pyrrolidine to form the 3 - pyrrolidine enamine, converting this to its 20-semicarbazone, hydrolysing this to 6[alpha],16[alpha] - dimethylprogesterone 20 - semicarbazone and reducing this. 6[alpha],16[alpha] - Dimethyl - 4- pregnen - 3# - ol - 20 - one 20 - ethylene ketal is prepared by Oppenauer oxidation of 6,16[alpha]-dimethyl 5 - pregnen - 3# - ol - 20 - one 20 - ethylene ketal (itself prepared from the free 20- one) to give 6[alpha],16[alpha] - dimethyl - progesterone 20 - ethylene ketal and reduction of this. 6[alpha],16[alpha] - Dimethyl - 4 - pregnen - 3#,17[alpha],20- triol 3,20 - diacetate is prepared by reduction of 6[alpha],16[alpha] - dimethyl - 17[alpha] - acetoxy - progesterone and acetylation of the product. 6- Halo - 16 - methyl - progeaterones are prepared by reacting 3-enol ethers of the corresponding 6-unsubstituted progesterones with N-halosuccinimides to give 6#-products and, when required, epimerizing these to 6[alpha]-products. These and other starting materials can be converted to the corresponding #4'6-steroids by reaction with chloranil. 1[alpha],2[alpha]-methylene starting materials are prepared by dehydrogenation of #4 or #4,6 compounds to #1,4 or #1'4'6-compounds and reaction of these with trimethyl sulphoxonium iodide or diazomethane. 1[alpha],2[alpha]- Methylene - 6 - chloro - 16 - methyl - 6 - dehydroprogesterones are prepared by converting corresponding 6 - unsubstituted compounds to the 6[alpha],7[alpha]-epoxides, reacting these with HCl to give 1[alpha] - chloromethyl - 6 - chloro - 16 - methyl - 6 - dehydroprogesterones and treating these with a base the corresponding 6 - bromo compounds are prepared by converting the 1[alpha]-chloromethyl intermediates to their 6[alpha],7[alpha]-epoxides, reacting these with HBr and ring closing with collidine 6-fluoro compounds are prepared similarly by reaction with HF before dehydration with HBr and ring closure. 6[alpha]-Triluoromethyl-16- methyl-progesterones are prepared from the corresponding 6-unsubstituted 3-enol ethers and CF 3 I with subsequent acid treatment. Starting materials saturated in the 6,7-position can also be obtained by reduction of 6-dehydroprogesterones, the configuration of any 6-substituent depending on the method used. The steroids of the invention, which are stated to have ovulation-inhibiting, cycleinfluencing, anti-androgenic, gonadotrophin influencing, anti-estrogenic and/or anti-fertility properties, may be made up into pharmaceutical compositions for parenteral, enteral or topical application with suitable carriers.